JP2025513807A5 - - Google Patents
Info
- Publication number
- JP2025513807A5 JP2025513807A5 JP2024559585A JP2024559585A JP2025513807A5 JP 2025513807 A5 JP2025513807 A5 JP 2025513807A5 JP 2024559585 A JP2024559585 A JP 2024559585A JP 2024559585 A JP2024559585 A JP 2024559585A JP 2025513807 A5 JP2025513807 A5 JP 2025513807A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- iodophenyl
- thieno
- pyridine
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2205203.9 | 2022-04-08 | ||
| GBGB2205203.9A GB202205203D0 (en) | 2022-04-08 | 2022-04-08 | Combination with inhibitor |
| PCT/EP2023/059270 WO2023194583A1 (en) | 2022-04-08 | 2023-04-06 | Combination of a gremlin-1 antagonist with an inhibitor of ras-raf-mek-erk signalling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513807A JP2025513807A (ja) | 2025-04-30 |
| JP2025513807A5 true JP2025513807A5 (https=) | 2026-04-14 |
Family
ID=81653346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559585A Pending JP2025513807A (ja) | 2022-04-08 | 2023-04-06 | グレムリン－１アンタゴニストとＲａｓ－Ｒａｆ－ＭＥＫ－ＥＲＫシグナル伝達の阻害剤の組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250228826A1 (https=) |
| EP (1) | EP4504777A1 (https=) |
| JP (1) | JP2025513807A (https=) |
| KR (1) | KR20250004733A (https=) |
| CN (1) | CN119790069A (https=) |
| AU (1) | AU2023248696A1 (https=) |
| CA (1) | CA3255427A1 (https=) |
| GB (1) | GB202205203D0 (https=) |
| IL (1) | IL315760A (https=) |
| MX (1) | MX2024012313A (https=) |
| WO (1) | WO2023194583A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025090966A1 (en) * | 2023-10-26 | 2025-05-01 | Vevo Therapeutics, Inc. | Mek inhibitors, alone or in combination with cdk4/5 inhibitors, for use in treating cancer |
| WO2026027660A1 (en) | 2024-08-02 | 2026-02-05 | UCB Biopharma SRL | Formulations of anti-gremlin-1 antibodies |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DE69534347T2 (de) | 1994-01-31 | 2006-05-24 | Trustees Of Boston University, Boston | Bibliotheken aus Polyklonalen Antikörpern |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| ES2374068T3 (es) | 2002-12-03 | 2012-02-13 | Ucb Pharma, S.A. | Ensayo para identificar células productoras de anticuerpos. |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
| EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
| EA201591762A1 (ru) | 2013-03-14 | 2015-12-30 | Ридженерон Фармасьютикалз, Инк. | Человеческие антитела к grem1 |
| GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| MX2020013808A (es) | 2018-06-18 | 2021-05-27 | UCB Biopharma SRL | Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer. |
| US11633401B2 (en) * | 2018-07-06 | 2023-04-25 | Memorial Sloan Kettering Cancer Center | Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer |
| WO2022152290A1 (en) * | 2021-01-18 | 2022-07-21 | Suzhou Transcenta Therapeutics Co., Ltd. | Novel anti-gremlin1 antibodies |
-
2022
- 2022-04-08 GB GBGB2205203.9A patent/GB202205203D0/en not_active Ceased
-
2023
- 2023-04-06 JP JP2024559585A patent/JP2025513807A/ja active Pending
- 2023-04-06 KR KR1020247037223A patent/KR20250004733A/ko active Pending
- 2023-04-06 CN CN202380041917.3A patent/CN119790069A/zh active Pending
- 2023-04-06 CA CA3255427A patent/CA3255427A1/en active Pending
- 2023-04-06 EP EP23715888.6A patent/EP4504777A1/en active Pending
- 2023-04-06 US US18/854,625 patent/US20250228826A1/en active Pending
- 2023-04-06 IL IL315760A patent/IL315760A/en unknown
- 2023-04-06 WO PCT/EP2023/059270 patent/WO2023194583A1/en not_active Ceased
- 2023-04-06 AU AU2023248696A patent/AU2023248696A1/en active Pending
-
2024
- 2024-10-03 MX MX2024012313A patent/MX2024012313A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025513807A5 (https=) | ||
| RU2018110770A (ru) | Ингибиторы mdm2 и их комбинации | |
| HRP20191821T1 (hr) | Antiproliferativni spojevi i načini njihove uporabe | |
| JP2025501175A (ja) | 抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ | |
| CN111527103A (zh) | 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法 | |
| JP2014509593A5 (https=) | ||
| JP2021528400A5 (https=) | ||
| ES2736030T3 (es) | Politerapia para el tratamiento del cáncer de ovario | |
| US11845994B2 (en) | Response to EGFR blockade | |
| JP2013542228A5 (https=) | ||
| EP3773725A1 (en) | Treatment of trk-associated cancers | |
| KR20170098813A (ko) | 대장암 치료에 사용하기 위한 아필리모드 | |
| JP2016514710A5 (https=) | ||
| JP2014513097A5 (https=) | ||
| RU2013126485A (ru) | Использование производных 2-карбоксамид-циклоамино мочевины в лечении egfr-зависимых заболеваний или заболеваний с приобретенной резистентностью к агентам, нацеленным на члены egfr-семейства | |
| JP7852103B2 (ja) | 固形腫瘍を治療するためのｋｒａｓｇ１２ｃ阻害剤及びｅｇｆｒ阻害剤を含む方法及び組成物 | |
| AU2019408244B2 (en) | Quinoline derivatives for use in the treatment or prevention of cancer | |
| US12409178B2 (en) | Methods and compositions comprising a KRasG12C inhibitor and a VEGF inhibitor for treating solid tumors | |
| Riess et al. | Metastatic non-small cell lung cancer management: novel targets and recent clinical advances | |
| JP2025513807A (ja) | グレムリン－１アンタゴニストとＲａｓ－Ｒａｆ－ＭＥＫ－ＥＲＫシグナル伝達の阻害剤の組み合わせ | |
| RU2020134183A (ru) | Способ ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы | |
| CN110191897A (zh) | 用于预防暴露于诱导p38活化的癌症治疗的受试者的转移的治疗 | |
| RU2811417C2 (ru) | Производные хинолина для применения в лечении или предупреждении рака | |
| EA053102B1 (ru) | Комбинация конъюгата антитела и лекарственного средства и ингибитора atr | |
| Rodon1 et al. | Combining Targeted Therapies |